Deutsche Bank raised the firm’s price target on Roche (RHHBY) to CHF 250 from CHF 235 and keeps a Sell rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche reports 9M group sales CHF 44.98B vs. CHF 44.05B last year
- Roche sees 2024 core EPS growing in high single digit range
- Voyager Therapeutics selloff on UCB news ‘excessive,’ says Leerink
- Genentech announces topline one-year results from ELEVATUM study
- Roche receives FDA approval for Ventana CLDN18 RxDx Assay